These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 5696082)

  • 1. Purified influenza virus vaccine. A study of viral reactivity and antigenicity.
    Peck FB
    JAMA; 1968 Dec; 206(10):2277-82. PubMed ID: 5696082
    [No Abstract]   [Full Text] [Related]  

  • 2. Influenza vaccines purified by zonal ultracentrifugation.
    Filczak K; Semkow R; Wrzos H; Zakrzewski K; Zgorzelska K
    Acta Microbiol Pol A; 1973; 5(3):261-70. PubMed ID: 4769561
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical reactivity and immunogenicity of hemagglutinin influenza vaccine. II. Clinical reactions, hemagglutination-inhibitiong and strain and type-specific complement-fixing antibody responses in infants.
    Závadová H; Adam E; Vonka V; Domorázková E; Kratochvílová M; Burian V; Davenport FM
    Arch Gesamte Virusforsch; 1972; 36(1):53-61. PubMed ID: 5062439
    [No Abstract]   [Full Text] [Related]  

  • 4. A clinical and serologic comparison of standard and purified bivalent inactivated influenza vaccines.
    Finklea JF; Sandifer SH; Peck FB; Manos JP
    J Infect Dis; 1969 Dec; 120(6):708-12. PubMed ID: 4911903
    [No Abstract]   [Full Text] [Related]  

  • 5. Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation.
    Mostow SR; Schoenbaum SC; Dowdle WR; Coleman MT; Kaye HS
    Postgrad Med J; 1973 Mar; 49(569):152-8. PubMed ID: 4802501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to influenza in ferrets. 8. Serological response of ferrets to influenza virus vaccines after infection with heterotypic strains of influenza.
    McLaren C; Potter CW
    Med Microbiol Immunol; 1973 Sep; 159(1):53-62. PubMed ID: 4769893
    [No Abstract]   [Full Text] [Related]  

  • 7. Potentiation of the antibody response to inactivated A2-Hong Kong vaccines by previous heterotypic influenza virus infection.
    Potter CW; Jennings R; Marine WM; McLaren C
    Microbios; 1973; 8(30):101-10. PubMed ID: 4801251
    [No Abstract]   [Full Text] [Related]  

  • 8. IMMUNOLOGIC STUDIES OF PURIFIED VIRAL HEMAGGLUTININ.
    TONG MJ; FONG J
    J Immunol; 1964 Jul; 93():35-44. PubMed ID: 14214387
    [No Abstract]   [Full Text] [Related]  

  • 9. The protection of ferrets against influenza by immunization with a split influenza vaccine.
    Brady MI; Furminger IG
    Dev Biol Stand; 1975; 28():167-72. PubMed ID: 1126566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical reactivity and immunogenicity of hemagglutinin influenza vaccine. I. Clinical reactions, hemagglutination-inhibiting and strain and type-specific complement-fixing antibody responses in subjects aged 3-6, 16-17 and 27-50 years.
    Závadová H; Vonka V; Adam E; Domorázková E; Davenport FM
    Arch Gesamte Virusforsch; 1972; 36(1):43-52. PubMed ID: 4551961
    [No Abstract]   [Full Text] [Related]  

  • 11. A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity.
    Brady MI; Furminger IG
    J Hyg (Lond); 1976 Oct; 77(2):173-80. PubMed ID: 1068196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antigenicity of various influenza vaccines in man].
    Kuwert E; Höhner PG; Bertrams J; Schriever O
    Dtsch Med Wochenschr; 1971 May; 96(22):938-45. PubMed ID: 4325348
    [No Abstract]   [Full Text] [Related]  

  • 13. Envelope protein of influenza virus. II. Antigenicity.
    Eckert EA
    Arch Environ Health; 1970 Sep; 21(3):316-20. PubMed ID: 5504433
    [No Abstract]   [Full Text] [Related]  

  • 14. Antineuraminidase antibody response of man to influenza virus neuraminidase N2: results obtained with an improved hemagglutination inhibition technique and an enzyme inhibition test.
    Hennessy AV; Minuse E; Davenport FM
    J Immunol; 1972 Aug; 109(2):213-6. PubMed ID: 5047368
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of preinfection and preimmunization on the serum antibody response to subsequent immunization with heterotypic influenza vaccines.
    Jennings R; Potter CW; McLaren C
    J Immunol; 1974 Dec; 113(6):1834-43. PubMed ID: 4547776
    [No Abstract]   [Full Text] [Related]  

  • 16. Age-related response to 1000 CCA unit zonally purified, inactivated influenza vaccines in volunteers in the U.S.A.
    Marine WM; Thomas JE
    Postgrad Med J; 1973 Mar; 49(569):164-8. PubMed ID: 4802389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of partial immunity to influenza by a neuraminidase-specific vaccine.
    Couch RB; Kasel JA; Gerin JL; Schulman JL; Kilbourne ED
    J Infect Dis; 1974 Apr; 129(4):411-20. PubMed ID: 4593871
    [No Abstract]   [Full Text] [Related]  

  • 18. Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man.
    Mostow SR; Schoenbaum SC; Dowdle WR; Coleman MT; Kaye HS; Hierholzer JC
    Am J Epidemiol; 1970 Oct; 92(4):248-56. PubMed ID: 5458217
    [No Abstract]   [Full Text] [Related]  

  • 19. The antigenic subunits of influenza viruses. I. The homologous antibody response.
    Fazekas de Saint Groth ; Webster RG; Davenport FM
    J Immunol; 1969 Nov; 103(5):1099-106. PubMed ID: 5350969
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunochemical studies on myxoviruses. I. Heterogeneity of V-antigens obtained y disruption influenza viruses.
    Neurath AR; Rubin BA; Pierzchala WA
    Z Naturforsch B; 1967 Aug; 22(8):850-5. PubMed ID: 4384763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.